BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 36948240)

  • 21. Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer.
    Suzawa K; Offin M; Lu D; Kurzatkowski C; Vojnic M; Smith RS; Sabari JK; Tai H; Mattar M; Khodos I; de Stanchina E; Rudin CM; Kris MG; Arcila ME; Lockwood WW; Drilon A; Ladanyi M; Somwar R
    Clin Cancer Res; 2019 Feb; 25(4):1248-1260. PubMed ID: 30352902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Going After
    Cancer Discov; 2019 Aug; 9(8):OF9. PubMed ID: 31209157
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION.
    Kato T; Yang JC; Ahn MJ; Sakai H; Morise M; Chen YM; Han JY; Yang JJ; Zhao J; Hsia TC; Berghoff K; Bruns R; Vioix H; Lang S; Johne A; Le X; Paik PK
    Br J Cancer; 2024 Jun; 130(10):1679-1686. PubMed ID: 38575731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer.
    Saigi M; McLeer-Florin A; Pros E; Nadal E; Brambilla E; Sanchez-Cespedes M
    Clin Transl Oncol; 2018 Jul; 20(7):881-888. PubMed ID: 29139039
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Durable responses to immunotherapy of non-small cell lung cancers harboring MET exon-14-skipping mutation: A series of 6 cases.
    Mayenga M; Assié JB; Monnet I; Massiani MA; Tabeze L; Friard S; Fraboulet S; Métivier AC; Chouaïd C; Zemoura L; Longchampt E; Callens C; Melaabi S; Couderc LJ; Doubre H
    Lung Cancer; 2020 Dec; 150():21-25. PubMed ID: 33045465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes.
    Mazieres J; Vioix H; Pfeiffer BM; Campden RI; Chen Z; Heeg B; Cortot AB
    Clin Lung Cancer; 2023 Sep; 24(6):483-497. PubMed ID: 37451931
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study.
    Horn L; Infante JR; Reckamp KL; Blumenschein GR; Leal TA; Waqar SN; Gitlitz BJ; Sanborn RE; Whisenant JG; Du L; Neal JW; Gockerman JP; Dukart G; Harrow K; Liang C; Gibbons JJ; Holzhausen A; Lovly CM; Wakelee HA
    Clin Cancer Res; 2018 Jun; 24(12):2771-2779. PubMed ID: 29563138
    [No Abstract]   [Full Text] [Related]  

  • 28. Capmatinib in
    Wolf J; Seto T; Han JY; Reguart N; Garon EB; Groen HJM; Tan DSW; Hida T; de Jonge M; Orlov SV; Smit EF; Souquet PJ; Vansteenkiste J; Hochmair M; Felip E; Nishio M; Thomas M; Ohashi K; Toyozawa R; Overbeck TR; de Marinis F; Kim TM; Laack E; Robeva A; Le Mouhaer S; Waldron-Lynch M; Sankaran B; Balbin OA; Cui X; Giovannini M; Akimov M; Heist RS;
    N Engl J Med; 2020 Sep; 383(10):944-957. PubMed ID: 32877583
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study.
    Shimokawa M; Nosaki K; Seto T; Ohashi K; Morise M; Horinouchi H; Sakakibara J; Murakami H; Yano S; Satouchi M; Matsumoto S; Goto K; Yoh K
    Trials; 2020 Mar; 21(1):298. PubMed ID: 32228679
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung Cancer.
    Kim EK; Kim KA; Lee CY; Kim S; Chang S; Cho BC; Shim HS
    Clin Lung Cancer; 2019 Jan; 20(1):e123-e132. PubMed ID: 30391211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial.
    Horn L; Wang Z; Wu G; Poddubskaya E; Mok T; Reck M; Wakelee H; Chiappori AA; Lee DH; Breder V; Orlov S; Cicin I; Cheng Y; Liu Y; Fan Y; Whisenant JG; Zhou Y; Oertel V; Harrow K; Liang C; Mao L; Selvaggi G; Wu YL
    JAMA Oncol; 2021 Nov; 7(11):1617-1625. PubMed ID: 34473194
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis.
    Awad MM; Leonardi GC; Kravets S; Dahlberg SE; Drilon A; Noonan SA; Camidge DR; Ou SI; Costa DB; Gadgeel SM; Steuer CE; Forde PM; Zhu VW; Fukuda Y; Clark JW; Jänne PA; Mok T; Sholl LM; Heist RS
    Lung Cancer; 2019 Jul; 133():96-102. PubMed ID: 31200835
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Clinical Impact of Capmatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification.
    Choi W; Park SY; Lee Y; Lim KY; Park M; Lee GK; Han JY
    Cancer Res Treat; 2021 Oct; 53(4):1024-1032. PubMed ID: 33540494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring
    Le X; Hong L; Hensel C; Chen R; Kemp H; Coleman N; Ciunci CA; Liu SV; Negrao MV; Yen J; Xia X; Scheuenpflug J; Stroh C; Juraeva D; Tsao A; Hong D; Raymond V; Paik P; Zhang J; Heymach JV
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34957368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.
    Schrock AB; Frampton GM; Suh J; Chalmers ZR; Rosenzweig M; Erlich RL; Halmos B; Goldman J; Forde P; Leuenberger K; Peled N; Kalemkerian GP; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
    J Thorac Oncol; 2016 Sep; 11(9):1493-502. PubMed ID: 27343443
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial.
    Yang Y; Zhou J; Zhou J; Feng J; Zhuang W; Chen J; Zhao J; Zhong W; Zhao Y; Zhang Y; Song Y; Hu Y; Yu Z; Gong Y; Chen Y; Ye F; Zhang S; Cao L; Fan Y; Wu G; Guo Y; Zhou C; Ma K; Fang J; Feng W; Liu Y; Zheng Z; Li G; Wu N; Song W; Liu X; Zhao S; Ding L; Mao L; Selvaggi G; Yuan X; Fu Y; Wang T; Xiao S; Zhang L
    Lancet Respir Med; 2020 Jan; 8(1):45-53. PubMed ID: 31628085
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of
    Yu Y; Zhang Q; Zhang J; Lu S
    J Cancer Res Ther; 2019; 15(4):909-913. PubMed ID: 31436251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Capmatinib in Japanese patients with MET exon 14 skipping-mutated or MET-amplified advanced NSCLC: GEOMETRY mono-1 study.
    Seto T; Ohashi K; Sugawara S; Nishio M; Takeda M; Aoe K; Moizumi S; Nomura S; Tajima T; Hida T
    Cancer Sci; 2021 Apr; 112(4):1556-1566. PubMed ID: 33506571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MET exon 14 skipping mutation positive non-small cell lung cancer: Response to systemic therapy.
    Wong SK; Alex D; Bosdet I; Hughesman C; Karsan A; Yip S; Ho C
    Lung Cancer; 2021 Apr; 154():142-145. PubMed ID: 33667719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interstitial lung disease associated with capmatinib therapy in a patient with non-small cell lung cancer harboring a skipping mutation of MET exon 14.
    Kanemura H; Takeda M; Shimizu S; Nakagawa K
    Thorac Cancer; 2021 Feb; 12(4):549-552. PubMed ID: 33347701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.